Mycoplasma Testing Market Consumption and Revenue Forecast by Regions 2027

Posted on 2022-05-11 by researchinsights in Biotech // 0 Comments

Mycoplasma Testing Industry Overview

The global mycoplasma testing market size was valued at USD 627.16 million in 2019 and is expected to witness attractive growth over the forecast period.

Increasing investments in R&D activities have contributed to huge revenue for the market. The rising introduction of novel technologies by key players is expected to further boost growth. The rise in cell culture contamination is also another factor driving growth.

Due to the limitation of culture methods, researchers are involved in the identification and development of more rapid and accurate mycoplasma tests in recent years. The primary advantages of such rapid tests would be high sensitivity, the capability of identifying a wide range of mycoplasma species, and cycle time reduction, thus, reducing the production time. These rapid methods would also facilitate faster decision making to minimize the spread of contamination. One such example of an alternative method for culture-based testing is Nucleic Acid-based Technology (NAT) which allows rapid detection of mycoplasma in cell culture. In 2018, American Type Culture Collection announced the launch of its new Polymerase Chain Reaction (PCR) based service that helps detect contaminants in mycoplasma cell cultures.

Gather more insights about the market drivers, restrains and growth of the Global Mycoplasma Testing Market

Increasing research activities conducted by pharmaceutical and biotechnology companies are resulting in the adoption of new technologies for drug discovery and development. In 2018, Boehringer Ingelheim announced its plans to invest around USD 259 million for its new Biologicals Development Center (BDC), to be located at its R&D site in Germany. Merck is also planning to invest USD 16 billion in R&D over the next five years, in addition to its annual investment of USD 7 billion. Thus, a huge amount of spending in R&D activities is expected to drive developments in this field, thereby boosting the demand for mycoplasma testing products.

Research activities in the pharmaceutical and biotechnology sectors are increasingly supported by various government authorities. For instance, the U.S. government is providing financial support to the global pharmaceutical companies in order to facilitate research-based activities for new drug development. In April 2019, the U.S. Food and Drug Administration (FDA) announced its plan to amend the regulations pertaining to the only testing method used for the detection of mycoplasma. According to the agency, the regulation is restrictive in nature and thus, prevents the use of other testing methods which may have the potential to accurately detect mycoplasma. Such changes in biologics regulation are expected to improve sensitivity and specificity in mycoplasma detection tests, evolving new technologies. Thus, an increase in government funding for pharmaceutical and biotechnology research has stimulated R&D activities, thereby, fostering the huge application of mycoplasma testing products.

More than 190 mycoplasma species are known, out of which only eight are responsible for more than 95% of cell culture contaminations. Poor cultural practices, dust, aerosols, and cross-contamination due to faulty or broken laminar flow are some of the factors due to which there is an increase in the number of cell culture contamination events. Additionally, mycoplasma contamination adversely affects the research work of scientists in laboratories. Human mycoplasma is a key source of cell culture contamination that occurs due to laboratory technicians who are infected with M. orale or M. fermentans. Hence, testing of such bacteria is considered as a significant requirement to generate robust data in the field of biomedical research.

Matched content

Editor’s pick